As Ki67 inhibition is one of the therapeutic effects of Sorafenib, we detected Ki67 in the tumor cells and found significant reduction in Sorafenib+ZLDI-8 treatment groups (Figs. 4 and 5). Here, MKI67 is linked to neoplasm.